Counts of positive / neutral / negative news items — not a price chart.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
The items moving the net sentiment the most, by direction and influence.
Medicare to Cover Obesity Drugs for the First Time, Opening a Major New Market for Eli Lilly's Zepbound
Direct news · High influence · Long term
Medicare GLP-1 Coverage Bridge Expands Market for Eli Lilly's Mounjaro and Zepbound
Drug pricing / FDA / IRA · Medium influence · Long term
CMS Proposes Extending Medicare Drug Price Negotiations to 2029, Pressuring Big Pharma Revenue
Drug pricing / FDA / IRA · Medium influence · Long term
IRA Drug Pricing Implementation and PBM Reform Both on CMS Agenda, Pressuring CVS and UnitedHealth
Drug pricing / FDA / IRA · Low influence · Long term
US Court Upholds Drug Pricing Regulation Against Pharma Challenge, Removing Legal Safety Net
Drug pricing / FDA / IRA · Low influence · Long term
Macro, commodity, FX and regulatory forces that moved LLY in this range, with the stories behind each.
Sign up free to track LLY, unlock full history and the complete driver breakdown, and get alerts when sentiment shifts.
Track LLY — freeInformational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
Also monitored for LLY (no news in this range): 10-Year Treasury yield.
